Compound to starve cancers of sugar-based building blocks found
November 19th, 2010 - 5:12 pm ICT by ANIWashington, Nov 19 (ANI): Scientists have discovered a compound that could be used to starve cancers of their sugar-based building blocks.
The compound, called a glutaminase inhibitor, has been tested on laboratory-cultured, sugar-hungry brain cancer cells and, the scientists say, may have the potential to be used for many types of primary brain tumors.
The Johns Hopkins scientists warned that glutaminase inhibitors have not been tested in animals or humans, but their findings may spark new interest in the glutaminase pathway as a target for new therapies.
Glutaminase is an enzyme that controls how glucose-based nutrients are converted into the carbon skeleton of a cell.
Additional enzymes that help construct the so-called “bricks” of the carbon skeleton are controlled by a gene called IDH1. In some brain cancer cells, IDH1 is mutated and the resulting enzyme grinds up the bricks into nutrients that feed cancer cells.
“Cancer cells with mutated IDH1 become addicted to the glutaminase pathway, and this pathway may represent an Achilles’ heel of cancer cells,” said Chi Dang of the Johns Hopkins University.
“To combat cancer, we might block the flow of materials that help create the bricks, starting with glutaminase,” said Dang.
The Johns Hopkins scientists and a team of chemists and geneticists at Princeton University used a glutaminase-blocking agent on cells engineered to have IDH1 mutations. The compound, called BPTES, reduced growth of the cancer cells by 30 percent.
“The glutaminase inhibitor we tested does not completely stop cancer cell growth, but slows it down,” said Gregory Riggins, of Johns Hopkins.
Riggins identified BPTES’ anticancer potential after screening many compounds for their glutaminase-blocking activity.
Dang said, “We can envision a day when patients who have IDH1 mutations are given a glutaminase inhibitor in addition to therapies that target other genomic aspects specific to their cancer.”
Their findings were published online November 2 in Cancer Research. (ANI)
- New 'poison' discovery could pave way for leukaemia therapy - Dec 04, 2010
- New path discovered for colon cancer drug discovery - Nov 20, 2010
- Gene mutation 'key to glioma brain cancer growth' - Nov 23, 2009
- Small molecules 'could block cell proliferation in cancerous human tumor' - Apr 14, 2011
- Synthetic compound may lead to drugs to fight pancreatic, lung cancer - Mar 10, 2011
- Genome code for most common form of pediatric brain cancer cracked - Dec 17, 2010
- 'Key player' that facilitates Parkinson's disease found - Mar 04, 2011
- Blocking rogue gene could halt the spread of most cancers - Jan 25, 2011
- Scientists identify four anti-cancer compounds - Nov 30, 2011
- Enzyme crucial to DNA replication may be potent anti-cancer drug target - Apr 15, 2011
- New discovery in the fight against Huntington's disease - Nov 28, 2010
- Key pathway implicated in progression of childhood cancer found - Sep 19, 2010
- Arsenic could be a potential cancer treatment - Jul 13, 2010
- New hope in the fight against melanoma - Dec 14, 2010
- Scientists link two gene mutations to most common brain cancers - Feb 19, 2009
Tags: achilles heel, brain cancer, brain tumors, bricks, building blocks, cancer cell growth, cancer cells, cancers, carbon skeleton, chemists, dang, geneticists, hopkins scientists, johns hopkins university, mutations, pathway, primary brain tumors, princeton university, riggins, target